Overview

About Axcelon Biopolymers

Axcelon Biopolymers Corporation is an innovative biomaterials company focused on leveraging its unique Bacterial NanoCellulose (BNC) platform technology to develop bacterial cellulose-based, high value products for wound care, medical devices, and industrial applications.

Axcelon is unique among early stage medical device companies. The Company is positioned to generate attractive near-term revenues from a licensed ready-to-market product and has impressive mid and long-term prospects for developing innovative and proprietary materials from its platform technology. This healthy combination will enable Axcelon to leverage the revenues and experience gained in the near-term to fully exploit the Company’s significant long-term prospects.

.

Three Key Business Areas

The Company operates in three key business areas:

1. Axcelon Dermacare Inc. - Commercial wound care division now selling Nanoderm™, a high clinical impact and cost effective wound care product, with a follow-on product launch (Nanoderm™Ag) in 2017

2. Axcelon Biomedical – R&D division developing a strong biomaterial-based medical device pipeline with significant licensing and revenue potential

3. Axcelon Biomaterials – R&D division developing a novel, disruptive technology in bacterial cellulose production for non-medical and industrial applications

Axcelon’s Business Model & Strategy

Axcelon is focused on becoming a world leader in the development and manufacturing of novel and cost-efficient bacterial cellulose-based products for the biomedical device industry and for non-medical industrial applications.

Our business model involves developing bacterial cellulose-based biomaterials and products to a stage where they can be licensed to commercial partners for specific therapeutic areas. Axcelon is also looking for co-development partnership opportunities to accelerate its development pipeline.